Citrate Salt Tablet Formulation for Stability and Powder Handling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Imidazo[1,2-a]pyridine compounds and their pharmaceutically acceptable salts exhibit poor formulation stability, leading to difficulties in industrialization and poor bioavailability, especially in the treatment of gastrointestinal inflammatory diseases and gastric acid-related diseases.
Innovation Solution
A pharmaceutical formulation comprising azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone citrate salt as the active ingredient, combined with microcrystalline cellulose and other excipients, to enhance stability, bioavailability, and tabletability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the citrate salt of Compound 1 is used as the active ingredient, then bioavailability is significantly improved, but powder handling becomes very difficult due to high scattering properties and sticky property
Solution Approach 1:
The patent introduces an intermediary substance (excipient) that mediates between the citrate salt of Compound 1 and the formulation process. The excipient acts as a carrier that absorbs the harmful scattering and sticky properties of the citrate salt powder, enabling easy handling while maintaining the bioavailability benefits of the citrate salt form.
Solution Approach 2:
The patent creates a composite material system by combining the citrate salt of Compound 1 with specific excipients in defined ratios. This composite formulation maintains the high bioavailability of the citrate salt while the excipient components provide good flowability and handling characteristics, effectively resolving the contradiction between improved bioavailability and difficult powder handling.
2Speed
If the citrate salt of Compound 1 is formulated, then dissolution rate is improved, but formulation stability deteriorates due to agglomeration and irregular scattering
Solution Approach 1:
The excipient serves as an intermediary that prevents direct interaction between citrate salt particles, thereby preventing agglomeration. This intermediary substance maintains the dissolution rate benefit of the citrate salt form while ensuring formulation stability by preventing particle aggregation and irregular scattering throughout the formulation process and storage.
Solution Approach 2:
The patent changes physical parameters of the formulation system by adjusting particle size, moisture content, and excipient ratios. These parameter changes prevent agglomeration of the citrate salt while maintaining its high dissolution rate, thus resolving the contradiction between fast dissolution and formulation stability.
3Ease of manufacture
If direct compression is used for tableting, then manufacturing simplicity is improved, but tabletability deteriorates due to poor flowability
Solution Approach 1:
The excipient acts as an intermediary that improves the flowability of the citrate salt of Compound 1 during the direct compression process. This intermediary substance enables simple direct compression manufacturing while ensuring good tabletability by providing adequate flow characteristics, thus resolving the contradiction between manufacturing simplicity and tabletability.
4Reliability
If the citrate salt of Compound 1 is stored long-term, then bioavailability is maintained, but physical and chemical stability deteriorates under temperature and humidity changes
Solution Approach 1:
The excipient serves as a protective intermediary that shields the citrate salt of Compound 1 from environmental factors during long-term storage. This intermediary substance maintains the bioavailability of the active ingredient while providing physical and chemical stability by preventing degradation under temperature and humidity changes throughout the storage period.
Data Source
Figure 1
AI summary
The present invention relates to a pharmaceutical formulation, a preparation method therefor and a tablet composition. The pharmaceutical formulation according to the present invention comprises an azetidin-1-yl{8-[(2,6- dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl} methanone citrate salt as an active ingredient, and microcrystalline cellulose as an excipient.